Table 3.
Comparison of empagliflozin with other SGLT2 inhibitors in diabetic patients.
| Authors | Suzuki et al. [101] | Täger et al. [102] | Jiang et al. [103] | Tang et al. [104] | Hussain et al. [105] |
|---|---|---|---|---|---|
| Year | 2022 | 2021 | 2022 | 2016 | 2021 |
| Study design | Clinical trial | Meta-Analysis | Meta-Analysis | Meta-Analysis | RCT |
| All Patients | 25,315 | 74,874 | 70,574 |
29,859 | 280 |
| Patient Category | Diabetic patients with recently implemented SGLT2 inhibitor therapy | 52–69 years old; HbA1C 7.2–9.3% | T2DM patients treated with SGLT2 inhibitors | adults with T2DM | T2DM with HbA1C 7.5–11% with different first line anti-diabetic drugs combination |
| Type of treatment | dapagliflozi, empagliflozin, canagliflozi, other SGLT2 inhibitors (tofogliflozi, ipragliflozin and luseogliflozin) | canagliflozin, dapagliflozin, empagliflozin or ertugliflozin (for at least 24 weeks) | placebo; dapagliflozin 2,5 mg, 5 mg, 10 mg; empagliflozin 10 mg, 25 mg; canagliflozin 100 mg, 300 mg | SGLT2 inhibitor vs. placebo or other anti-diabetic treatment | empagliflozin 10–25 mg vs. dapagliflozin 5–10 mg daily as add on therapy |
| Comparison of empagliflozin with other SGLT2 inhibitors | No significant differences in risk of MI, stroke, AF, HF and AP between patients treated with individual SGLT2 inhibitors. | Empagliflozin, dapagliflozin and canagliflozin similarly reduced HF worsening. Empagliflozin is more effective than canagliflozin and dapagliflozin in reducing all-cause mortality and cardiovascular mortality. |
Empagliflozin is more effective than canagliflozin and dapagliflozin in reducing cardiovascular events and all-cause mortality. | Neither empagliflozi, canagliflozin nor dapagliflozin was associated with increased risk of all-cause mortality and CV outcomes. Empagliflozin may have a protective effect. | Comparing with dapagliflozi, empagliflozin caused a more significant improvement in body weight, fasting blood sugar and HbA1c over a period of 12 weeks and caused less adverse effects. |
SGLT2 inhibitors, sodium-glucose cotransporter-2 inhibitors; MI, myocardial infarction; AF, atrial fibrillation; HF, heart failure; AP, angina pectoris; CV, cardiovascular; RCT, randomized controlled trial.